Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

NCT07083960 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics West LLC as lead sponsor.

NCT NCT07083960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07083960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Lead sponsor
Lakefront Biotherapeutics West LLC
Phase
Phase 1
Overall status
Recruiting
Start date
August 1, 2025
Completion date
September 30, 2027
Enrollment
32 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

aiha - cold autoimmune hemolytic anemia, aiha - warm autoimmune hemolytic anemia, itp - immune thrombocytopenia